Our group previously reported that an active targeted nanoparticle drug delivery system mediated by FSHR has a high selectivity for FSHR-positive ovarian cancer cells, and that the nanoparticles modified with FSH β 33–53 or β 81–95 peptide deliver more chemotherapeutic drugs into ovarian cancer cells and significantly enhance the antitumor efficacy of chemotherapeutic drugs [8,9,23]. The gene discussed is FSHR; the disease is ovarian carcinoma.